What Are the Alternatives to Retatrutide?

What the Phase 3 program reported

Eli Lilly released topline TRIUMPH-1 results on May 21, 2026, in 2,339 randomized adults. In the 12 mg arm at 80 weeks, weight reduction was 28.3 percent on the efficacy estimand against 2.2 percent on placebo, and 25.0 percent on the treatment-regimen estimand against 3.9 percent on placebo. Those two labels answer different questions rather than ranking each other. The efficacy estimand estimates outcomes had participants stayed on assigned treatment without starting prohibited weight-management therapy; the treatment-regimen estimand estimates the effect regardless of adherence or of starting such therapy. A 532-participant extension enrolled people with BMI of 35 or above who completed the 80-week study and tolerated their assigned dose, continuing at a maximum tolerated dose of 9 mg or 12 mg; the 12 mg cohort within that extension reached 30.3 percent at 104 weeks. That figure describes one arm of a selected cohort, not the trial population. Most common adverse events in the 12 mg arm versus placebo included nausea at 42.4 versus 14.8 percent, diarrhea at 32.0 versus 13.5 percent, constipation at 26.1 versus 10.9 percent, vomiting at 25.3 versus 4.8 percent, and upper respiratory tract infection at 13.1 versus 11.6 percent. On July 23, 2026 Lilly reported that TRIUMPH-2 and TRIUMPH-3 also met their primary endpoints, in adults with type 2 diabetes and in adults with severe obesity and established cardiovascular disease respectively, with weight reduction of up to 20.8 percent and up to 22.6 percent at 80 weeks. The same release said Lilly is completing its manufacturing data package and plans to submit in the first quarter of 2027. That is forward-looking company guidance about a filing, not an approval date.

The approved options

• Semaglutide, tirzepatide, liraglutide, and orforglipron are FDA approved for weight management and prescribable through a clinician. This is a non-exhaustive list of incretin-based examples, not a ranking and not a recommendation.
• Orforglipron was approved on April 1, 2026 and is the first small-molecule GLP-1 taken as a pill for weight management, which matters mostly to people whose objection to the category is injections.
• What these have that the trial-stage group does not is an approved label, a regulated supply chain, and a clinician who can prescribe and monitor. They are single or dual receptor agonists rather than the triple-receptor design retatrutide uses.

The trial-stage compounds people compare it against

• VK2735, survodutide, amycretin, cagrilintide, petrelintide, and pemvidutide are not FDA approved and sit at various trial phases.
• Mazdutide is not FDA approved or prescribable in the US, but it is approved in China, for chronic weight management since June 2025 and for glycemic control in type 2 diabetes since September 2025. Approval in one country is not approval in another.
• None of the group is prescribable for weight loss in the US today, so choosing among them is not a choice between products.
• Head-to-head profiles live on the compare pages linked below rather than being restated here, so the numbers stay in one place and cannot drift apart.

About natural alternatives to retatrutide

This is a common search and the honest answer is narrower than either marketing or dismissal suggests. Some supplements do have placebo-controlled weight studies behind them. What we found no registered or published example of is a head-to-head comparison against retatrutide or against any approved incretin drug, so nothing here supports treating one as an equivalent or a replacement.

Pepdex rule

Pepdex does not tell you to switch compounds and does not sell any of them. Which drug fits a person depends on medical history, other conditions, and cost, and that is a conversation with a clinician. What belongs on a page like this is the approval status and the trial record, checked against the source rather than repeated from a forum.

More alternatives answers